The OTIs Clinical Research Center is very pleased to be a part of this important clinical trial. In October 2012, $2.5 million grant was awarded to a team consisted of Microbion Corporation, University of Pennsylvania, and University of California San Francisco (UCSF) to help facilitate Phase 2 human trials to treat post-surgical orthopedic infections with Microbions innovative antimicrobial drug. The clinical studies will be carried out at both the Hospital of the University of Pennsylvania, and at UCSF/Zuckerberg San Francisco General as well as two additional sites. A team of researchers led by Samir Mehta, MD, chief of the Orthopaedic Trauma & Fracture Service at the Perelman School of Medicine at the University of Pennsylvania, will work with Microbion and Dr. Saam Morshed from the University of California-San Francisco on the trial. At the OTI, Dr. Saam Morshed will be the site PI on the study and Dr. Utku Kandemir will serve as co-investigator. UCSF will be receiving a sub-ward of the DOD grant from university of Pennsylvania and additional funding from Micorbion to help conduct the trial. On June 10, 2016, a site initiation visit was conducted at the OTI by Microbion Corporation and Medpace (the CRO). We are looking forward to start recruiting study participants very soon. We plan to recruit and follow a total of 12 patients at UCSF/ZSFG. READ MORE HERE
